Compare HUTCHMED (China) Ltd. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months
- Poor long term growth as Operating profit has grown by an annual rate 12.33% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -888.56
2
Risky -
3
Underperformed the market in the last 1 year
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
12.51%
0%
12.51%
6 Months
-8.68%
0%
-8.68%
1 Year
-6.32%
0%
-6.32%
2 Years
-12.09%
0%
-12.09%
3 Years
14.09%
0%
14.09%
4 Years
-20.41%
0%
-20.41%
5 Years
0%
0%
0.0%
HUTCHMED (China) Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
22.83%
EBIT Growth (5y)
12.33%
EBIT to Interest (avg)
-888.56
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.69
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
3.79%
Valuation key factors
Factor
Value
P/E Ratio
6
Industry P/E
Price to Book Value
2.14
EV to EBIT
-69.61
EV to EBITDA
-183.11
EV to Capital Employed
-32.38
EV to Sales
2.28
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
37.76%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'21 - YoY
Jun'21
Jun'20
Change(%)
Net Sales
588.70
427.80
37.61%
Operating Profit (PBDIT) excl Other Income
-625.40
-354.00
-76.67%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-461.90
-254.40
-81.56%
Operating Profit Margin (Excl OI)
-1,062.40%
-827.50%
-23.49%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2021 is 37.61% vs 9.05% in Jun 2020
Consolidated Net Profit
YoY Growth in quarter ended Jun 2021 is -81.56% vs -33.26% in Jun 2020
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
4,276.20
4,917.40
-13.04%
Operating Profit (PBDIT) excl Other Income
-425.50
-254.50
-67.19%
Interest
22.30
22.40
-0.45%
Exceptional Items
-0.70
-37.50
98.13%
Consolidate Net Profit
3,568.50
297.80
1,098.29%
Operating Profit Margin (Excl OI)
-99.50%
-71.30%
-2.82%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -13.04% vs -25.05% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 1,098.29% vs -62.38% in Dec 2024
About HUTCHMED (China) Ltd. 
HUTCHMED (China) Ltd.
Pharmaceuticals & Biotechnology
Hutchison China Meditech Limited is an investment holding company principally engaged in the manufacture and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Manufacturing Business segment is engaged in the manufacture and distribution of drug products. The Distribution Business segment provides sales and marketing services to pharmaceutical manufacturers. The Company's products include prescription and over the counter (OTC) pharmaceuticals such as banlangen, fu fang dan shen tablets and shexiang baoxin pills and others, and consumer health products. In addition, the Company also develops targeted therapeutics and immunotherapies for oncology and autoimmune diseases.
Company Coordinates 
Company Details
22Nd Floor Hutchison House, 10 Harcourt Road None : 00000
Registrar Details






